Fortress Biotech

Fortress Biotech company information, Employees & Contact Information

Explore related pages

Related company profiles:

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has seven marketed prescription pharmaceutical products and over 20 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital and Sentynl.
Looking for a particular Fortress Biotech employee's phone or email?

Fortress Biotech Questions

News

Fortress Biotech and Subsidiary Urica Therapeutics Announce - GlobeNewswire

Fortress Biotech and Subsidiary Urica Therapeutics Announce GlobeNewswire

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - Yahoo Finance

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Yahoo Finance

Fortress Biotech and Cyprium Therapeutics Receive Complete Response Letter from FDA for CUTX-101 NDA for Menkes Disease Treatment | FBIO Stock News - Quiver Quantitative

Fortress Biotech and Cyprium Therapeutics Receive Complete Response Letter from FDA for CUTX-101 NDA for Menkes Disease Treatment | FBIO Stock News Quiver Quantitative

$205M Series A: Fortress Biotech's Gout Drug Partner Crystalys Advances Global Phase 3 Trials - Stock Titan

$205M Series A: Fortress Biotech's Gout Drug Partner Crystalys Advances Global Phase 3 Trials Stock Titan

Biotech Innovation Leader Fortress Biotech Joins H.C. Wainwright Global Investment Conference 2025 - Stock Titan

Biotech Innovation Leader Fortress Biotech Joins H.C. Wainwright Global Investment Conference 2025 Stock Titan

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference GlobeNewswire

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing - citybiz

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing citybiz

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - Yahoo Finance

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights Yahoo Finance

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA - GlobeNewswire

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA GlobeNewswire

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - Yahoo Finance

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights Yahoo Finance

Fortress Biotech Earnings: Triple Win with $28M Checkpoint Deal, FDA Fast-Track, and Rosacea Drug Launch - Stock Titan

Fortress Biotech Earnings: Triple Win with $28M Checkpoint Deal, FDA Fast-Track, and Rosacea Drug Launch Stock Titan

Journey Medical Corporation to Participate in September 2025 Investor Conferences - GlobeNewswire

Journey Medical Corporation to Participate in September 2025 Investor Conferences GlobeNewswire

Fortress Biotech Announces FDA Approval of Emrosi for Rosacea Treatment and Details Upcoming PDUFA for Cosibelimab - Quiver Quantitative

Fortress Biotech Announces FDA Approval of Emrosi for Rosacea Treatment and Details Upcoming PDUFA for Cosibelimab Quiver Quantitative

Fortress Biotech Announces Reverse Stock Split - Yahoo Finance

Fortress Biotech Announces Reverse Stock Split Yahoo Finance

Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd. - Yahoo Finance

Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd. Yahoo Finance

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 - GlobeNewswire

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 GlobeNewswire

Journey Medical Corporation Reports Combined Emrosi™ - GlobeNewswire

Journey Medical Corporation Reports Combined Emrosi™ GlobeNewswire

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for GlobeNewswire

Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program - Yahoo Finance

Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program Yahoo Finance

Cyprium Therapeutics, a Fortress Biotech Partner Company, - GlobeNewswire

Cyprium Therapeutics, a Fortress Biotech Partner Company, GlobeNewswire

Fortress Biotech’s Partner Company, Journey Medical - GlobeNewswire

Fortress Biotech’s Partner Company, Journey Medical GlobeNewswire

Journey Medical Corporation Enters into a Definitive - GlobeNewswire

Journey Medical Corporation Enters into a Definitive GlobeNewswire

FBIO Stock Price and Chart — NASDAQ:FBIO - TradingView

FBIO Stock Price and Chart — NASDAQ:FBIO TradingView

Top Fortress Biotech Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant